Associations - pegylated liposomal doxorubicin

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline ifosfamide + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline ifosfamide + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline cisplatin + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2
LRP1B overexpression	Ovarian Cancer	LRP1B overexpression	Ovarian Cancer	pegylated liposomal doxorubicin Sensitive: C3 – Early Trials pegylated liposomal doxorubicin Sensitive : C3	pegylated liposomal doxorubicin Sensitive: C3 – Early Trials pegylated liposomal doxorubicin Sensitive : C3
NF1 mutation	Soft Tissue Sarcoma	NF1 mutation	Soft Tissue Sarcoma	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3
HRD	Soft Tissue Sarcoma	HRD	Soft Tissue Sarcoma	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3
BRCA2 deletion	Soft Tissue Sarcoma	BRCA2 deletion	Soft Tissue Sarcoma	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3	ifosfamide + pegylated liposomal doxorubicin Resistant: C3 – Early Trials ifosfamide + pegylated liposomal doxorubicin Resistant : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials carboplatin + pegylated liposomal doxorubicin Sensitive : C3	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials carboplatin + pegylated liposomal doxorubicin Sensitive : C3
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials carboplatin + pegylated liposomal doxorubicin Sensitive : C3	carboplatin + pegylated liposomal doxorubicin Sensitive: C3 – Early Trials carboplatin + pegylated liposomal doxorubicin Sensitive : C3
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	pegylated liposomal doxorubicin + trabectedin Sensitive: C3 – Early Trials pegylated liposomal doxorubicin + trabectedin Sensitive : C3	pegylated liposomal doxorubicin + trabectedin Sensitive: C3 – Early Trials pegylated liposomal doxorubicin + trabectedin Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	pegylated liposomal doxorubicin + trabectedin Sensitive: C3 – Early Trials pegylated liposomal doxorubicin + trabectedin Sensitive : C3	pegylated liposomal doxorubicin + trabectedin Sensitive: C3 – Early Trials pegylated liposomal doxorubicin + trabectedin Sensitive : C3
BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	BRCA1 2110_2111delAA + BRCA1 4071_4096 +14del40 + TP53 R342P + NOTCH2 Q1310H	Ovarian Cancer	carboplatin + pegylated liposomal doxorubicin Resistant: C4 – Case Studies carboplatin + pegylated liposomal doxorubicin Resistant : C4	carboplatin + pegylated liposomal doxorubicin Resistant: C4 – Case Studies carboplatin + pegylated liposomal doxorubicin Resistant : C4

pegylated liposomal doxorubicin

Associations
(31)

Associations
(31)

pegylated liposomal doxorubicin

Associations(31)

Associations(31)

Associations
(31)

Associations
(31)